Wall Street brokerages expect Ascendis Pharma A/S (NASDAQ:ASND) to report earnings per share of ($0.92) for the current quarter, according to Zacks. Three analysts have issued estimates for Ascendis Pharma A/S’s earnings, with the highest EPS estimate coming in at ($0.79) and the lowest estimate coming in at ($1.05). Ascendis Pharma A/S reported earnings per share of ($0.55) in the same quarter last year, which would suggest a negative year over year growth rate of 67.3%. The company is scheduled to issue its next earnings report on Wednesday, March 28th.
On average, analysts expect that Ascendis Pharma A/S will report full year earnings of ($3.99) per share for the current financial year, with EPS estimates ranging from ($4.43) to ($3.55). For the next financial year, analysts expect that the firm will report earnings of ($3.22) per share, with EPS estimates ranging from ($3.86) to ($2.86). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Ascendis Pharma A/S.
ASND has been the topic of a number of analyst reports. Bank of America lowered their target price on shares of Ascendis Pharma A/S from $46.00 to $43.00 and set a “buy” rating on the stock in a report on Friday, November 17th. HC Wainwright reissued a “buy” rating on shares of Ascendis Pharma A/S in a report on Wednesday, December 13th. BidaskClub raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. JPMorgan Chase & Co. set a $50.00 price target on shares of Ascendis Pharma A/S and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Finally, Zacks Investment Research cut shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $52.67.
Shares of Ascendis Pharma A/S (NASDAQ:ASND) traded down $3.15 during mid-day trading on Friday, reaching $63.80. 149,112 shares of the company’s stock were exchanged, compared to its average volume of 257,060. Ascendis Pharma A/S has a 1-year low of $21.95 and a 1-year high of $69.00. The company has a market cap of $2,780.02, a PE ratio of -17.53 and a beta of 0.68.
Institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. bought a new position in shares of Ascendis Pharma A/S in the third quarter worth $194,000. Aperio Group LLC bought a new position in shares of Ascendis Pharma A/S in the third quarter worth $241,000. Quantitative Systematic Strategies LLC bought a new position in shares of Ascendis Pharma A/S in the fourth quarter worth $269,000. Jane Street Group LLC bought a new position in shares of Ascendis Pharma A/S in the third quarter worth $352,000. Finally, Citadel Advisors LLC bought a new position in Ascendis Pharma A/S in the third quarter valued at $372,000. 73.48% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/09/0-92-earnings-per-share-expected-for-ascendis-pharma-a-s-asnd-this-quarter.html.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.